An Update on Monoclonal Antibody Therapy to Treat Moderate-to-Severe Asthma: Benefits, Choices, and Limitations

Am J Med. 2023 Aug;136(8):738-744. doi: 10.1016/j.amjmed.2023.05.001. Epub 2023 May 18.


Moderate or severe asthma is a complex disease process clinically manifesting as at least partially reversible airway obstruction due to airway hyperresponsiveness. Asthma therapy was based primarily on symptom control until recent studies of its mechanisms have led to a host of new targeted, safe, and effective therapies. These biologic therapies directly attack culprit inflammatory mediators at the molecular level. In this article we review currently available biologic agents for the treatment of moderate-to-severe asthma. We provide information deemed necessary to optimally consult with an asthma specialist to choose, assist in financial arrangements for, and coordinate the use of these new, promising, Food and Drug Administration-approved biologic agents. We will also briefly review the molecular pathways targeted with each class of biologic to provide a more in-depth understanding of why these targeted therapies are effective. These biologics are the first of many to come that modify newly discovered components of the immune system with which many physicians are unfamiliar.

Keywords: Asthma; Biologics; Monoclonal antibody; Treatment.

Publication types

  • Review

MeSH terms

  • Anti-Asthmatic Agents* / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Asthma* / drug therapy
  • Biological Factors / therapeutic use
  • Biological Products* / therapeutic use
  • Humans
  • Immunotherapy


  • Antibodies, Monoclonal
  • Biological Factors
  • Biological Products
  • Anti-Asthmatic Agents